麗珠醫藥(01513.HK)與韓資訂立獨家協議 許可費1,500萬美元
麗珠醫藥(01513.HK)公布,與韓資Onconic簽署授權許可協議。據此,公司獲一項獨家許可,可在內地、香港、澳門及台灣開發、製造和商業化鉀離子競爭性酸阻滯劑(P-CAB)Zastaprazan。
協議生效後,公司應向Onconic支付許可費1,500萬美元;產品開發及上市銷售階段,應向Onconic支付技術轉移費用、相應的開發里程碑金及銷售里程碑金共計不超過1.13億美元;以及相應的銷售提成。
Zastaprazan是Onconic自主研發的一款創新P-CAB,目前正在韓國開展針對糜爛性食管炎的III期臨床試驗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.